X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
1
Enter email and you're done. No subscription, no credit card.
2
Search, tap and you're done. Over 3,400 medicines.
3
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Apixaban (Eliquis) is the most prescribed modern blood thinner in Germany — and the main reason why fewer brain hemorrhages occur on anticoagulation today. Around two million people in Germany have atrial fibrillation, the most common indication (a German figure, broadly comparable across Western countries). Unlike warfarin, apixaban needs no INR monitoring — instead, reliable twice-daily intake determines the protection.
See more detail.gif)
Never stop or pause apixaban on your own – not even before operations or during bleeding. At signs of a brain haemorrhage (sudden headache, neurological deficits) or after a fall with a head knock: call 112 immediately. Last updated: May 2026.
Apixaban is the most prescribed direct oral anticoagulant (DOAC) in Germany. Below are the key facts for quick orientation – the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Apixaban |
| Brand name | Eliquis (originator), apixaban generics |
| ATC code | B01AF02 |
| Drug class | Direct oral anticoagulant (DOAC) / factor Xa inhibitor |
| Mechanism | Direct reversible inhibition of factor Xa |
| Bioavailability | About 50% |
| Half-life | About 12 hours (hence twice-daily intake) |
| Renal excretion | About 27% (markedly less than other DOACs) |
| Dosage form | Film-coated tablets (2.5 mg, 5 mg) |
| Usual dosage | 5 mg or 2.5 mg twice daily (indication-dependent) |
| Antidote | Andexanet alfa (Ondexxya); PCC as a reserve option |
| Prescription | Yes |
| Most important note | Never stop on your own – not even before an operation or during bleeding |
Scroll table right
Apixaban – known by the brand name Eliquis – is a direct oral anticoagulant (DOAC), a modern agent for thinning the blood. It belongs to the subgroup of factor Xa inhibitors and is the most prescribed DOAC in Germany and many other countries. Apixaban prevents the formation of dangerous blood clots and thereby protects against strokes, thromboses and pulmonary embolisms.
Apixaban was introduced in 2011 and has since – like the other DOACs – largely replaced classic anticoagulation with vitamin K antagonists (warfarin/phenprocoumon) in many indications. The decisive advantage: apixaban works in a fixed dose without regular clotting checks (no INR monitoring needed), has fewer food interactions and a faster onset of action.
Important to understand: apixaban is not a “blood thinner” in the literal sense – the blood does not become more fluid. Rather, blood clotting is inhibited so that no dangerous clots can form. It is a balancing act: on one hand protection against thromboses and strokes, on the other an increased bleeding risk. Understanding and managing this tightrope walk correctly is the key to safe therapy.
Apixaban directly and reversibly inhibits clotting factor Xa (“ten-a”) – a central hub of blood clotting. Factor Xa catalyses the conversion of prothrombin to thrombin, which in turn converts fibrinogen to fibrin – the “glue” holding a clot together. By inhibiting factor Xa, the entire clotting cascade is interrupted at a key point.
Unlike heparin (which inhibits factor Xa only indirectly via antithrombin), apixaban acts directly on factor Xa – hence the name “direct” oral anticoagulant. Unlike vitamin K antagonists (warfarin), which suppress the formation of several clotting factors over days, apixaban acts selectively and rapidly on a single hub.
Apixaban is well absorbed after oral intake (bioavailability about 50%), reaches peak plasma levels after 3 to 4 hours and has a half-life of about 12 hours – hence the twice-daily intake. Excretion is about 27% via the kidneys (markedly less than other DOACs) and mainly via liver and gut. Metabolism runs partly via CYP3A4 and the P-glycoprotein (P-gp) – the source of the most important interactions.
The comparatively low renal excretion makes apixaban the preferred choice in patients with impaired kidney function – a clinically very relevant advantage over dabigatran (80% renal) and rivaroxaban (35% renal).
Apixaban has four main indications – all to prevent or treat dangerous blood clots:
| Indication | Dosage | Duration |
|---|---|---|
| Stroke prevention in atrial fibrillation (non-valvular) | 5 mg twice daily (or 2.5 mg twice daily) | Long-term therapy |
| Acute deep vein thrombosis (DVT) / pulmonary embolism | 10 mg twice daily for 7 days, then 5 mg twice daily | At least 3–6 months |
| Extended maintenance after DVT/PE | 2.5 mg twice daily | After at least 6 months of acute treatment |
| Thromboprophylaxis after hip replacement | 2.5 mg twice daily | 32–38 days |
| Thromboprophylaxis after knee replacement | 2.5 mg twice daily | 10–14 days |
Scroll table right
The main indication is stroke prevention in atrial fibrillation. In the pivotal ARISTOTLE trial, apixaban was even superior to warfarin for stroke prevention – with a lower bleeding risk at the same time. The indication is set via the CHA2DS2-VASc score. In acute thrombosis or pulmonary embolism, the advantage over the classic heparin–warfarin scheme is that apixaban can be given orally from the start.
The correct dose is decisive – both under- and overdosing can be dangerous. The most important dose-adjustment rule concerns stroke prevention in atrial fibrillation:
| Situation | Dose | Note |
|---|---|---|
| Atrial fibrillation (standard) | 5 mg twice daily | About 12 hours apart |
| Atrial fibrillation (dose reduction) | 2.5 mg twice daily | With at least 2 of 3: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL |
| Acute thrombosis / pulmonary embolism | 10 mg twice daily | For 7 days, then 5 mg twice daily |
| Extended maintenance after DVT/PE | 2.5 mg twice daily | Lower recurrence at low bleeding risk |
| Thromboprophylaxis hip/knee | 2.5 mg twice daily | 10–38 days depending on procedure |
| Severe renal impairment (eGFR 15–29) | With caution, often 2.5 mg twice daily | Close monitoring |
| Dialysis / eGFR < 15 | Not recommended | Insufficient data |
Scroll table right
The most important comparison for many patients switching from a vitamin K antagonist or starting anticoagulation. Both drug classes prevent clots, but differ fundamentally:
| Aspect | Vitamin K antagonist (e.g. phenprocoumon) | Apixaban (Eliquis) |
|---|---|---|
| Clotting control | Regular INR checks, dose adjustment | Fixed dose, no routine monitoring |
| Onset | After days (heparin bridging needed) | Within hours |
| Food | Sensitive to vitamin-K foods | Independent of them |
| Interactions | Numerous interactions | Markedly fewer, but not none |
| Antidote | Vitamin K / PCC | Andexanet alfa |
| Bleeding risk | Higher (especially brain haemorrhage) | Lower |
| Cost | Much cheaper | More expensive (partly offset by dropping the monitoring) |
| Mechanical heart valves | Still standard | Contraindicated |
Scroll table right
Clinical rule of thumb: for most patients with atrial fibrillation or thrombosis, DOACs such as apixaban are the first choice today – because of better handling and safety. Vitamin K antagonists remain indispensable for mechanical heart valves, severe renal impairment and certain other constellations.
There are four DOACs on the market. They differ mainly in mechanism, kidney dependence and dosing frequency:
| DOAC | Mechanism | Renal excretion | Frequency | Remark |
|---|---|---|---|---|
| Apixaban (Eliquis) | Factor Xa inhibitor | 27% | Twice daily | Favourable in renal impairment |
| Rivaroxaban (Xarelto) | Factor Xa inhibitor | 35% | Once daily | Take with a meal |
| Edoxaban (Lixiana) | Factor Xa inhibitor | 50% | Once daily | – |
| Dabigatran (Pradaxa) | Thrombin inhibitor (IIa) | 80% | Twice daily | Own antidote idarucizumab |
Scroll table right
Clinical placement: apixaban is regarded as a very safe choice thanks to its good bleeding profile and low kidney dependence – especially in older and renally impaired patients. Rivaroxaban scores with once-daily intake (better compliance). The choice of DOAC depends on kidney function, comorbidities, co-medication and individual factors.
The most important safety topic with any anticoagulation. Apixaban – like all anticoagulants – increases the bleeding risk. The art is to assess and manage this risk correctly. A distinction is made between minor and major bleeding:
Call 112 immediately
For heavy, unstoppable bleeding, sudden severe headache with neurological deficits (speech, vision, movement problems – suspected brain haemorrhage), black tarry stool or vomiting blood, sudden severe abdominal pain, or circulatory weakness with pallor and cold sweat (suspected internal bleeding): call the emergency number 112.
Risk factors for bleeding: older age, impaired kidney function, low body weight, previous bleeding, stomach ulcers, concurrent use of NSAIDs, ASA or other blood thinners, uncontrolled high blood pressure, alcohol abuse. The HAS-BLED score helps assess the risk – but it does not lead to abandoning anticoagulation, rather to optimising the risk factors.
Since apixaban is taken twice daily and clotting protection depends on regular intake, handling missed doses matters:
One missed dose vs. repeated forgetting
A single missed dose is usually uncritical because the half-life is about 12 hours. But: repeated forgetting endangers clotting protection and increases the risk of stroke or thrombosis. Reliable intake is especially important with DOACs because – unlike with warfarin – there is no check (INR) to reveal gaps.
Before planned operations or invasive procedures, apixaban usually has to be paused temporarily – for how long depends on the bleeding risk of the procedure and the kidney function. An important difference from warfarin: with DOACs no heparin “bridging” is usually needed, because they act quickly and are cleared quickly.
Pausing always doctor-controlled
Pausing before procedures must always be doctor-controlled – never on your own. Before every planned procedure (including at the dentist!), the anticoagulation should be discussed with the treating doctor. An unnecessary pause increases the thrombosis risk, a missing pause the bleeding risk.
A major advance in the safety of DOAC therapy: for apixaban (and rivaroxaban) there is a specific antidote – andexanet alfa (brand name Ondexxya). It is used in life-threatening or uncontrolled bleeding under factor Xa inhibitors and can rapidly reverse the anticoagulant effect.
Andexanet alfa is a modified factor Xa molecule that binds the apixaban molecules and thus “catches” them – the body’s own factor Xa can then work normally again. The antidote is kept in specialised emergency departments and hospitals.
As a reserve option, if the antidote is not available, PCC (prothrombin complex concentrate) is used, which replaces the missing clotting factors. For dabigatran there is a separate antidote (idarucizumab / Praxbind). The availability of these antidotes has considerably improved the safety of DOAC therapy and dispelled some of the early reservations.
The most important “side effect” is the increased bleeding risk (own chapter). Beyond that, the following can occur:
| Side effect | Frequency / description |
|---|---|
| Bleeding of various kinds | Most common side effect – nosebleeds, bleeding gums, bruises, heavier periods |
| Anaemia | From chronic small blood losses – can lead to iron-deficiency anaemia |
| Nausea | Occasional, usually mild |
| Raised liver values | Rare, usually reversible |
| Skin reactions | Itching, rash – occasional |
| Dizziness, headache | Occasional |
| Allergic reactions | Rare – up to anaphylaxis; stop immediately and seek care |
| Thrombocytopenia | Very rare – reduction of platelets |
Scroll table right
Compared with other anticoagulants, apixaban is overall well tolerated – apart from the inherent bleeding risk. Gastrointestinal complaints are rarer than with dabigatran.
Apixaban is metabolised via CYP3A4 and P-glycoprotein (P-gp) – substances that affect these systems change the apixaban levels. The interactions fall into three categories:
| Category | Substances | Effect / recommendation |
|---|---|---|
| Directly increasing bleeding risk | NSAIDs (ibuprofen, diclofenac, naproxen) | Considerable GI bleeding risk – avoid if possible, otherwise gastric protection with a PPI |
| Directly increasing bleeding risk | ASA, clopidogrel | Combined bleeding risk – only with a clear indication |
| Directly increasing bleeding risk | Other anticoagulants (heparin, warfarin, DOACs) | Never together without a clear transition indication |
| Directly increasing bleeding risk | SSRIs / SNRIs (sertraline, citalopram, venlafaxine) | Slightly increased bleeding risk – keep an eye on it |
| CYP3A4/P-gp inhibitor (raises level) | Ketoconazole, itraconazole, posaconazole | Avoid combination or reduce dose |
| CYP3A4/P-gp inhibitor | HIV protease inhibitors (ritonavir) | Avoid combination |
| CYP3A4/P-gp inhibitor | Clarithromycin (macrolide) | With caution – use another antibiotic if needed |
| CYP3A4/P-gp inducer (lowers level) | Carbamazepine, phenytoin, phenobarbital | Can weaken the protective effect |
| CYP3A4/P-gp inducer | Rifampicin | Marked weakening of effect |
| CYP3A4/P-gp inducer | St John’s wort | Can dangerously reduce the apixaban effect – never combine! |
Scroll table right
More in drug interactions and taking medication correctly.
An important and frequently asked question. With apixaban: moderate alcohol consumption is usually acceptable, excessive consumption is problematic. The reasons:
Practical recommendation: occasional moderate alcohol consumption (e.g. a glass of wine) is unproblematic for most patients. Regular or heavy consumption should be avoided. With liver disease or an increased fall risk, particular restraint is advisable. When in doubt, discuss with the treating doctor.
An important advantage of apixaban: it is only excreted about 27% via the kidneys – markedly less than other DOACs. Apixaban is therefore often the preferred choice in patients with impaired kidney function.
| Kidney function (eGFR) | Recommendation |
|---|---|
| Normal to mildly impaired (≥ 60) | Standard dosing |
| Moderately impaired (30–59) | Standard dosing, dose reduction per the general criteria if needed |
| Severely impaired (15–29) | With caution, often reduced dose (2.5 mg twice daily) |
| Dialysis / eGFR < 15 | Officially not recommended – use only in individual cases after careful weighing |
Scroll table right
Important: regular monitoring of kidney function at least yearly, more often with impaired function. With acute worsening of kidney function (e.g. dehydration, infection) review the dose. More in chronic kidney disease.
Older patients benefit especially from stroke prevention in atrial fibrillation – while at the same time having a higher bleeding risk. Apixaban is regarded as a good choice for this group thanks to its favourable safety profile:
Have it checked promptly if the following occurs under apixaban:
Call 112 immediately
For sudden severe headache with neurological deficits (speech, vision, movement problems – suspected brain haemorrhage), vomiting blood or black tarry stool, heavy unstoppable bleeding, sudden severe abdominal pain, circulatory weakness with pallor and cold sweat, or after a fall or head injury (even without a visible external injury – risk of internal bleeding!): call 112.
The most important behavioural rules for safe apixaban therapy:
Transparency note
brite is a health app. The following functions relate to features of the app and do not replace medical care.
Anonymised observations from brite app user data; do not replace clinical studies.
| Observation | Frequency | Typical comment |
|---|---|---|
| Double dose after forgetting | Common | “I forgot and thought I’d just make it up – the app warned me.” |
| NSAID self-medication | Common | “For a headache I took ibuprofen – no one had warned me.” |
| St John’s wort for low mood | Rare, but critical | “My naturopath recommended St John’s wort – the app blocked it.” |
| Not informing the dentist | Common | “I thought a simple cleaning didn’t matter – the dentist was astonished.” |
| Not checked after a fall | Occasional | “After a fall onto the sofa, no doctor’s visit – the app reminded me.” |
| Anticoagulant ID card forgotten | Common | “At the emergency doctor the card was missing – he didn’t know what I take.” |
Scroll table right
Apixaban is overall very well tolerated. The most common side effects are minor bleeds (nosebleeds, bleeding gums, more bruising) – usually easily manageable. Serious side effects are rare. Compared with warfarin, many patients benefit from the simpler handling (no INR checks, no diet restrictions). The pivotal ARISTOTLE trial even showed apixaban superior to warfarin for stroke prevention – with a lower bleeding risk at the same time.
The twice-daily intake is more demanding than the once-daily dosing of rivaroxaban or warfarin. What works: choose fixed times (e.g. 8:00 and 20:00), link the intake to routines (breakfast, dinner, tooth-brushing), set a reminder on your phone and use a weekly box. Important: with more than 6 hours’ delay, take the dose; with less than 6 hours, skip it – never double.
Most sports are possible and even recommended. Caution applies to contact and high-risk sports with an increased fall risk (mountain biking, skiing, martial arts, riding). Swimming, hiking, cycling on safe terrain, yoga and strength training are usually unproblematic. For sports with an injury risk, keep in touch with your doctor and take special protective measures if needed (helmet, protectors). In general: staying active is important – especially with atrial fibrillation and a thrombosis risk.
The switch from a vitamin K antagonist to apixaban is doctor-controlled. Typical course: stop the vitamin K antagonist, check the INR, and once the INR falls below 2.0, start apixaban. Overlapping intake is not needed (unlike the warfarin start with heparin). Important: do not switch on your own – the exact timing depends on the current INR value and the individual situation. After the switch, no more INR checks are needed.
Apixaban (Eliquis) was long expensive because it was patent-protected. Since the patent expired, generics are available that contain the same active substance in the same quality – usually much cheaper. The pharmacy can substitute a generic (aut-idem rule) if the doctor permits it. Effect and safety are identical. Patients may have to get used to a possibly different tablet appearance and pack sizes, but the therapy remains equally effective.
